Public evidence gap ledger
A transparent index of the questions that could materially change current Registry ratings. These are not predictions about which compounds will work. They are the specific evidence gaps the current assessment still depends on.
Profiles with stated gaps
102
Curated gap statements
184
Ranking method
None - alphabetical only
Each item below is copied from the same curated field shown on the compound profile under What would change our rating? The ledger does not create a second AI-generated interpretation of the evidence.
A gap can be resolved by a positive, negative or null result. Filling a gap does not automatically raise a rating. It may strengthen, weaken or leave the current assessment unchanged.
A PTHrP-based anabolic peptide for osteoporosis, with labelling extended to men at high fracture risk.
An approved melanocortin implant for a rare light-sensitivity disease — not a tanning drug, whatever the internet says.
A growth-hormone fragment marketed for fat loss whose own obesity trials failed to establish a benefit.
An investigational antibody that inhibits myostatin activation, with a peer-reviewed Phase 2 trial showing less DXA-measured lean-mass loss during tirzepatide treatment, but no proven functional outcome in obesity.
An 11-amino-acid EPO-derived peptide with real randomised human data in one narrow neuropathy setting.
An investigational long-acting amylin receptor peptide agonist in Phase 1 studies for obesity, with no efficacy results in people.
A fixed-dose combination of two separate investigational peptides — amylin receptor agonist ASC36 and GLP-1/GIP agonist ASC35 — in Phase 1 for obesity.
An investigational peptide GIP receptor antagonist — it blocks the GIP receptor rather than activating it — in a Phase 2a study combined with semaglutide.
A synthetic single-chain peptide derived from the relaxin-2 B-chain that signals at RXFP1; evidence is cell and animal work only.
The internet's favourite healing peptide: a mountain of rodent data and almost no controlled human evidence.
An FDA-approved melanocortin agonist for one specific sexual-health diagnosis — endlessly mis-sold as a general performance enhancer.
An investigational dual GIP and GLP-1 receptor agonist now in Phase 3 trials for alcohol use disorder and major depressive disorder, with no efficacy results published.
A Khavinson-series tetrapeptide studied in a rat model of lung damage from nitrogen dioxide; no human study. Its reported sequence is inconsistent across sources.
A long-acting amylin analogue, now in its own Phase 3 programme as well as in combination therapy.
A salmon-derived hormone peptide once common in bone disease, now used more narrowly after regulators weighed modest benefit against a debated malignancy signal.
A long-acting oxytocin analogue approved in many countries — but not the US — to prevent uterine atony after delivery.
A Khavinson-series tetrapeptide tested on rat heart-tissue explants in a dish; not the CardioGen-82 heart-imaging agent, and not tested on living hearts.
A three-amino-acid Khavinson-series short peptide whose published evidence is cell-culture work, not human joint or cartilage outcomes.
An investigational localized fat-reduction small-molecule injection, studied for abdominal subcutaneous fat reduction rather than whole-body obesity treatment. Not a peptide.
The other widely used GnRH antagonist in assisted reproduction protocols.
A long-acting GHRH analogue abandoned after early human studies — it reliably raises growth hormone, but the outcomes it is sold for were never tested.
A GnRH antagonist approved for advanced prostate cancer — hormone suppression without the initial flare.
A V2-selective vasopressin analogue approved in nasal, oral and injectable formulations — each tied to its own specific indications.
A neuropeptide named for a sleep effect first described in the 1970s that decades of follow-up have never clearly replicated in humans.
An investigational selective amylin-pathway agonist now in a broad Phase 3 programme.
An experimental combination of the amylin receptor agonist eloralintide with tirzepatide, studied as a combination rather than a single new molecule.
The first HIV entry inhibitor — a 36-amino-acid peptide that blocks viral fusion.
An investigational GLP-1/GIP dual agonist reported to be advancing towards Phase 3.
Longevity claims built on an old, narrow and largely unreplicated body of research.
The first GLP-1 receptor agonist — born from Gila-monster venom peptide biology — with formulations ranging from twice-daily to weekly injection.
A branded follistatin-derived protein construct marketed with muscle-growth claims. No FLGR-242-specific animal outcome study, human study or registered human trial has been identified; related evidence is not compound-specific evidence.
Experimental senolytic peptide with cell and mouse evidence, but no established human efficacy or safety.
A GnRH antagonist used in assisted reproduction to time ovulation precisely.
FDA-approved in the US for the narrow adult FOP indication; metabolic and body-composition use remains investigational.
Decent cosmetic evidence on the skin, very different question when people inject it.
One of the original growth-hormone secretagogue peptides — real pharmacology, no approved physique indication, and formal FDA compounding safety concerns.
The older sibling of GHRP-2, with historical human pharmacology but no approved indication and a notable appetite-stimulating effect.
The body's own counter-insulin hormone, available as approved injection and nasal rescue products — another proof that 'nasal peptide' is not shorthand for experimental.
A GnRH agonist delivered as a small implant under the skin of the abdomen, suppressing sex hormones in prostate and breast cancer and certain gynaecological conditions.
A short mitochondria-targeted research peptide that binds cardiolipin. Evidence is cell and mouse work, including 2026 optic-nerve injury data.
A GnRH-agonist implant approved for central precocious puberty, releasing peptide continuously for about a year per implant.
A synthetic decapeptide that blocks bradykinin B2 receptors, approved for acute attacks of hereditary angioedema in adults.
A modified long-acting IGF-1 analogue sold for bodybuilding, and not the same thing as approved IGF-1 medicine.
A selective growth hormone secretagogue discontinued after its trials missed their endpoints — now sold for physique and recovery claims no trial ever tested.
A fragment of the body's own reproductive signalling peptide, studied in human physiology research but not an approved therapy.
A three-amino-acid fragment of alpha-MSH marketed for gut healing and inflammation, with no human clinical studies identified by the FDA.
A long-acting somatostatin analogue with pivotal-trial evidence for slowing tumour progression in certain neuroendocrine tumours.
A GnRH agonist whose depot injections switch off sex-hormone production — used in prostate cancer, endometriosis and central precocious puberty depending on the product.
A 14-amino-acid peptide swallowed as a capsule that works locally on the gut lining — approved oral proof that not every peptide is digested into uselessness.
The older once-daily GLP-1 agonist, with long real-world follow-up and modest effect sizes.
A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.
A human antimicrobial peptide studied topically for wound healing, now marketed for unrelated systemic uses.
A small indole-derived molecule — not a peptide — studied in cells and mice for mitochondrial disease. No human trial evidence in our record.
A GLP-1/glucagon dual agonist developed largely in Chinese trial populations.
An investigational long-acting GLP-1 and GIP receptor co-agonist prodrug in Phase 1, with only preliminary small-cohort sponsor-reported data.
A preclinical single-peptide construct reported to combine GLP-1, GIP and glucagon receptor activity with dual amylin and calcitonin receptor activity.
A preclinical triple GLP-1, GIP and glucagon receptor agonist prodrug nominated as a development candidate in August 2026.
A synthetic melanocortin peptide sold for tanning — unapproved everywhere, and routinely confused with genuinely approved melanocortin medicines.
A mitochondrial-derived peptide with genuinely interesting biology and thin translational data.
A GnRH agonist that has been an approved nasal-spray medicine for decades — the standing rebuttal to 'nasal peptide means research chemical'.
The foundational somatostatin analogue, used for acromegaly and symptom control in certain neuroendocrine tumours.
The natural wake-promoting neuropeptide; two small crossover studies tested intranasal dosing in narcolepsy. Not the same as approved orexin receptor drugs.
A distinct endogenous 28-amino-acid orexin peptide studied mainly in receptor, tissue and animal experiments; no verified human intervention was identified.
The natural nonapeptide hormone of labour and lactation, long approved as an IV/IM obstetric medicine.
A CNTF-derived, adamantylated tetrapeptide studied in Alzheimer's mouse models; no human trial identified. Not the same as 'P21'.
A broader-spectrum somatostatin analogue approved for specific endocrine disorders including Cushing's disease.
A rodent-stage antidepressant candidate being discussed online as a nootropic peptide.
A muscle-repair peptide with a compelling mechanism story and no robust human outcome evidence.
An investigational GLP-1/glucagon dual agonist now developed primarily for serious liver disease, not weight loss.
A long-acting amylin analogue in Phase 2, with Phase 3 weight-management trials planned.
A 20-amino-acid neuropeptide studied in animals and cultured cells across reproductive, gut and metabolic biology. No human trial evidence.
A Khavinson-series tripeptide (Glu-Asp-Arg) with cell and rodent neuroprotection studies; no independent controlled human trial identified.
A 16-amino-acid oral peptide modelled on the natural gut hormone uroguanylin, approved for chronic constipation and IBS-C in adults.
A 32-residue chimeric peptide (p53 residues 12–26 plus a membrane-penetrating leader) studied against cancer cells in the laboratory only.
A synthetic amylin analogue approved as an add-on in insulin-treated diabetes.
A tetrapeptide studied in cultured human lymphocytes; the cited work measured chromosome and chromatin changes, not prostate outcomes in patients.
A cell-penetrating peptide designed to block CXXC5 and boost Wnt signalling; it regrew hair in mice. No human hair-regrowth result has been shown.
An investigational GIP/GLP-1/glucagon triple agonist with positive pivotal Phase 3 results and no approval anywhere.
A synthetic heptapeptide related to tuftsin, marketed online for anxiety despite no regulatory approval and almost no independent human evidence.
A GLP-1 receptor agonist with one of the largest clinical trial programmes in modern metabolic medicine.
A synthetic heptapeptide derived from an ACTH fragment, registered as nasal drops in Russia and heavily marketed elsewhere as a nootropic.
An MC4R agonist approved for specific genetic obesity syndromes — precision medicine, not a general weight-loss drug.
A small-molecule research chemical — not a peptide — that activates the ERR nuclear receptors and increased running capacity in mice. No human data.
A mitochondria-targeting peptide with a narrow accelerated approval and a much broader set of unproven anti-ageing claims.
An investigational glucagon/GLP-1 dual agonist now supported by peer-reviewed Phase 3 obesity trials with and without type 2 diabetes.
A genuine biological protein with real research history, and a separate online product that is not quite the same thing.
A GLP-2 analogue that helps people with short bowel syndrome reduce dependence on intravenous nutrition.
A parathyroid-hormone fragment that builds bone — one of the few anabolic osteoporosis treatments.
A vasopressin analogue approved intravenously for hepatorenal syndrome — with a boxed warning about serious or fatal respiratory failure.
An approved medicine for one specific indication, routinely marketed for a much broader one.
A thymic immune peptide approved in dozens of countries for specific indications, but never approved in the US — and marketed far beyond any approval.
A dual GIP and GLP-1 receptor agonist with strong Phase 3 weight and glycaemic data.
An investigational myostatin-blocking antibody with controlled Phase 2 data on DXA-measured lean mass and MRI-measured thigh fat-free muscle volume alongside semaglutide, but no proven functional outcome.
A long-acting GnRH agonist depot used in prostate cancer and central precocious puberty.
The body's own antidiuretic nonapeptide, used intravenously in intensive care to support blood pressure in vasodilatory shock.
A Khavinson-series short peptide studied in cell cultures and by computer docking; no vascular benefit in people has been shown.
A dipeptide (Lys-Glu) studied in mouse immune cells, plus one older observational Russian report in people with diabetes; no controlled efficacy trial.
An investigational GLP-1/GIP dual agonist in Phase 3 as an injection, with an oral form behind it.
An investigational dual amylin and calcitonin receptor agonist that entered a first-in-human Phase 1 safety study in June 2026.
A preclinical single-molecule agonist reported to engage five receptors — GLP-1, GIP, glucagon, amylin and calcitonin — with no human data of any kind.
An investigational single-molecule GLP-1 and amylin receptor co-agonist now in Phase 3 obesity trials.
A cone-snail-venom-derived peptide painkiller given directly into spinal fluid for severe chronic pain.